Search Page

1

Cite

Share

A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.

Hipp S, Voynov V, Drobits-Handl B, Giragossian C, Trapani F, Nixon AE, Scheer JM, Adam PJ. Hipp S, et al. Among authors: giragossian c. Clin Cancer Res. 2020 Oct 1;26(19):5258-5268. doi: 10.1158/1078-0432.CCR-20-0926. Epub 2020 Jun 18. Clin Cancer Res. 2020. PMID: 32554516 Free article.

Cite

Share

2

Cite

Share

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.

Ma H, Wang H, Sove RJ, Jafarnejad M, Tsai CH, Wang J, Giragossian C, Popel AS. Ma H, et al. Among authors: giragossian c. AAPS J. 2020 Jun 12;22(4):85. doi: 10.1208/s12248-020-00450-3. AAPS J. 2020. PMID: 32533270 Free PMC article.

Cite

Share

3

Cite

Share

Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist.

García-Martínez JM, Wang S, Weishaeupl C, Wernitznig A, Chetta P, Pinto C, Ho J, Dutcher D, Gorman PN, Kroe-Barrett R, Rinnenthal J, Giragossian C, Impagnatiello MA, Tirapu I, Hilberg F, Kraut N, Pearson M, Kuenkele KP. García-Martínez JM, et al. Among authors: giragossian c. Mol Cancer Ther. 2021 Jan;20(1):96-108. doi: 10.1158/1535-7163.MCT-20-0253. Epub 2020 Oct 9. Mol Cancer Ther. 2021. PMID: 33037135 Free article.

Cite

Share

4

Cite

Share

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

Ahlberg J, Giragossian C, Li H, Myzithras M, Raymond E, Caviness G, Grimaldi C, Brown SE, Perez R, Yang D, Kroe-Barrett R, Joseph D, Pamulapati C, Coble K, Ruus P, Woska JR, Ganesan R, Hansel S, Mbow ML. Ahlberg J, et al. Among authors: giragossian c. MAbs. 2019 Jul;11(5):956-964. doi: 10.1080/19420862.2019.1615345. Epub 2019 Jun 4. MAbs. 2019. PMID: 31068073 Free PMC article.

Cite

Share

5

Cite

Share

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.

Ma H, Wang H, Sové RJ, Wang J, Giragossian C, Popel AS. Ma H, et al. Among authors: giragossian c. J Immunother Cancer. 2020 Aug;8(2):e001141. doi: 10.1136/jitc-2020-001141. J Immunother Cancer. 2020. PMID: 32859743 Free PMC article.

Cite

Share

6

Cite

Share

Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics.

Giragossian C, Clark T, Piché-Nicholas N, Bowman CJ. Giragossian C, et al. Curr Drug Metab. 2013 Sep;14(7):764-90. doi: 10.2174/13892002113149990099. Curr Drug Metab. 2013. PMID: 23952252 Review.

Cite

Share

7

Cite

Share

Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.

Weng Y, Ishino T, Sievers A, Talukdar S, Chabot JR, Tam A, Duan W, Kerns K, Sousa E, He T, Logan A, Lee D, Li D, Zhou Y, Bernardo B, Joyce A, Kavosi M, O'Hara DM, Clark T, Guo J, Giragossian C, Stahl M, Calle RA, Kriz R, Somers W, Lin L. Weng Y, et al. Among authors: giragossian c. Sci Rep. 2018 Mar 9;8(1):4241. doi: 10.1038/s41598-018-22456-w. Sci Rep. 2018. PMID: 29523796 Free PMC article.

Cite

Share

8

Cite

Share

Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development.

Ma H, Pilvankar M, Wang J, Giragossian C, Popel AS. Ma H, et al. Among authors: giragossian c. ACS Pharmacol Transl Sci. 2020 Dec 3;4(1):213-225. doi: 10.1021/acsptsci.0c00178. eCollection 2021 Feb 12. ACS Pharmacol Transl Sci. 2020. PMID: 33615174

Cite

Share

9

Cite

Share

Peptide hormone binding to G-protein-coupled receptors: structural characterization via NMR techniques.

Mierke DF, Giragossian C. Mierke DF, et al. Among authors: giragossian c. Med Res Rev. 2001 Sep;21(5):450-71. doi: 10.1002/med.1018. Med Res Rev. 2001. PMID: 11579442 Review.

Cite

Share

10

Cite

Share

Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.

Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang ZF, Ahlberg J, Bigwarfe T, Myzithras M, Waltz E, Roberts S, Kroe-Barrett R, Singh S. Yang D, et al. Among authors: giragossian c. MAbs. 2017 Oct;9(7):1105-1117. doi: 10.1080/19420862.2017.1359455. Epub 2017 Aug 8. MAbs. 2017. PMID: 28786732 Free PMC article.

Cite

Share